Emiko Ohki

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami et al. · Investigational New Drugs · 2012 · 63 citations · Full text

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong‐Wan Kim, Yi‐Long Wu et al. · Cancer Research and Treatment · 2017 · 57 citations · Full text

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib

Akihiko Gemma, Masahiko Kusumoto, Yasuyuki Kurihara et al. · Journal of Thoracic Oncology · 2018 · 48 citations · Full text

Inflammatory Lung Disease, Advanced Lung Disease, Alk-positive Nsclc +9

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida et al. · Investigational New Drugs · 2012 · 42 citations · Full text

Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium

Michinori Terada, Emiko Ohki, Yuka Yamagishi et al. · Journal of Infection and Chemotherapy · 2011 · 37 citations

Several Antibiotics, Health Sciences, Antibiotics +9